Dr. Michael Bowdish - Reflections on MSB's NIH Trial, page-116

Re the New York Times list, if you follow the link to the ClinicalTrials.gov list, MSB is number 28 on the list.
If you then deselect so you only keep phase 3 clinical trials in, then there are only 3.
One from Iran, with 60 pts, and a relatively uncontrolled MSC source, so pretty small trial although results this year, but Iranian, so altogether not big competition.
The third is US, 400 pts, started in April, but a phase 2/3, which means that they have to reach a pre-defined endpoint to move to the phase 3 component and their expected date of completion is end 2021. So they are significantly behind the MSB phase 3.

So altogether this reporter couldn’t see the woods for the trees at least when it came to mesenchymal stem cell potential - or possibly when it came to treatments for Covid-19, given that anti-virals will only have a real chance of working prior to someone being very unwell (Remdesivir) and that we have used dexamethasone in certain contexts out of sheer desperation anyway.

discussing different treatments required for different stages of disease might have been another way to go.....